Antonio Alma, Linda Pongetti, Alessandro Clementi, Johanna Chester, Matteo Toccaceli, Silvana Ciardo, Elena Zappia, Marco Manfredini, Giovanni Pellacani, Maurizio Greco, Luigi Bennardo, Francesca Farnetani
Introduction : Basal cell carcinoma (BCC) represents around 80% of all malignant skin cancers worldwide, constituting a substantial burden on healthcare systems. Due to excellent clearance rates (around 95%), surgery is the current gold-standard treatment. However, surgery is not always possible or preferred by patients. Numerous non-surgical therapies, sometimes combined, have been associated with promising tumor free survival rates (80-90%) in non-melanoma skin cancers (NMSCs). Most research has enrolled superficial basal cell carcinomas (sBCCs), with limited recent studies also involving low-risk nodular BCCs (nBCCs)...
December 24, 2023: Medicina